Voyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases
20 févr. 2018 07h00 HE
|
Voyager Therapeutics, Inc.
Collaboration to include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau Voyager to receive $69 million upfront payment and...